Medicaid Rebate Suit Focuses On FDA Approval Status Of Acthar's New Indication
Executive Summary
US government says Mallinckrodt avoided millions in Medicaid rebates by claiming Acthar’s added indication was approved as a new NDA rather than a supplemental application.